<DOC>
	<DOCNO>NCT01071915</DOCNO>
	<brief_summary>This open-label , multi-centre single arm trial investigate efficacy safety degarelix Korean patient prostate cancer bridge CS21 trial ( NCT00295750 ) result .</brief_summary>
	<brief_title>Efficacy Safety Degarelix One Month Dosing Regimen Korean Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has give write informed consent trialrelated activity perform . Has histologically confirm ( Gleason grade ) adenocarcinoma prostate ( stage ) ( except neoadjuvant hormonal therapy/ include patient rise PSA prostatectomy radiotherapy ) Is male patient age 18 year old Has screen serum testosterone level &gt; 1.5 ng/mL Has ECOG ( Eastern Cooperative Oncology Group ) score ≤ 2 Has screen PSA value ≥2 ng/mL Has life expectancy least 12 month Has previous currently hormonal management prostate cancer . However , prostatectomy radiotherapy curative intention , neoadjuvant/adjuvant hormonal therapy accept maximum duration 6 month , least 6 month prior Screening Visit Is currently treat 5αreductase inhibitor Is consider candidate curative therapy , i.e . radical prostatectomy radiotherapy Has history severe untreated asthma , anaphylactic reaction severe urticaria and/or angioedema Has hypersensitivity towards component investigational medicinal product A marked baseline prolongation QT/QTcF interval A history additional risk factor Torsade de Pointes ventricular arrhythmia Has cancer within last five year except prostate cancer surgically remove basal squamous cell carcinoma skin Has know suspect hepatic , symptomatic biliary disease Has elevate serum ALT level upper limit normal serum total bilirubin level upper level normal range Screening Visit confirm second measurement within 21 day Has clinically significant laboratory abnormality Has clinically significant disorder ( prostate cancer ) condition , include alcohol drug abuse Has mental incapacity language barrier preclude adequate understanding co operation Has receive investigational drug within last 28 day precede Screening Visit longer consider possibly influence outcome current trial Has previously participate degarelix trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>